Mission

The goals of the Molecular Imaging (MI) Program include the development and testing of new imaging methods ranging from preclinical work on the synthesis of new probes and development of new devices to the clinical evaluation of imaging approaches to assess cancer risk, detect cancer, guide treatment and monitor therapy. These imaging methods are aimed at improving our understanding of cancer physiology and providing for the integration of these findings to ultimately improve the assessment of cancer and its treatment. To achieve these goals we have two themes. 

Scientific Themes

  • Theme 1. Synthesis of new imaging agents for metabolism and drug pharmacodynamics
  • Theme 2. Implement and test new imaging agents and methods for risk assessment, detection, guidance and assessment of the response to therapy
  • Theme 3. Develop and test novel instrumentation for molecular imaging

Program Activities

The MI Program works to bring investigators together to expand collaborative activities with members of our program and other programs through:

  • Monthly program meetings which include speakers from within the MI Program, speakers from related disciplines and invited outside speakers. 
  • Joint meetings or mini-retreats with other programs to highlight particular areas of collaboration. 
  • Yearly retreats are held for the program to further foster collaboration among members
  • Organization of working groups to evaluate joint projects including multi-investigator pilot projects, protocols, and grants. 

Program Leaders

  • Nerissa Viola, Ph.D.

    Leader, Molecular Imaging Program
    Karmanos Cancer Institute
    Wayne State University School of Medicine

  • Anthony Shields, M.D., Ph.D.

    Co-Leader, Molecular Imaging Program
    Karmanos Cancer Institute
    Wayne State University School of Medicine

The Latest From Karmanos Cancer Institute

News

IN THE NEWS: Detroit Cancer Center Unveils New Device for Treating Liver Cancer at Home

The Detroit News The TheraBionic P1 device is now available for patients who have advanced liver cancer and have failed first- and second-line the...

Read More

Karmanos Cancer Institute Physicians Begin Prescribing New FDA-approved Radiofrequency Electromagnetic Device to Treat Advanced Liver Cancer

The Barbara Ann Karmanos Cancer Institute , the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announce...

Read More

CURE, in Collaboration with Karmanos' Office of Cancer Health Equity and Community Engagement, Educates the Community About Metastatic Breast Cancer

On Wednesday, Dec. 4, 2024, patients, survivors, and advocates gathered at Karmanos Cancer Institute in Detroit to learn about metastatic breast c...

Read More
News

WDET | Scholarship Program Aims to Encourage More Diversity in Clinical Trials

Listen Now

101 WRIF | Lung Cancer Awareness

Listen Now

Becker’s Healthcare Podcast | Exploring Breakthroughs in Cancer Treatment with Dr. Boris C. Pasche, President & CEO at Karmanos Cancer Institute

Listen Now